In a letter dated March 21, 2023, the National Institutes of Health (“NIH”) again refused the request of petitioners to exercise march-in rights under the Bayh-Dole Act to control the price of a drug.  Here, as before, the NIH found that the statutory criteria for the use of march-in rights were not satisfied by the…